New drug interaction study aims to prevent dangerous medication Mix-Ups
NCT ID NCT06367153
First seen May 22, 2026
Summary
This completed phase 1 trial in 18 healthy adults examined how multiple doses of the experimental drug BI 1569912 change the way the body processes three common medications: repaglinide (for diabetes), midazolam (for sedation), and bupropion (for depression or smoking cessation). By measuring drug levels in the blood, researchers aim to understand potential interactions and guide future safe use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
SGS Life Science Services - Clinical Research
Edegem, 2650, Belgium
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1569912
What this could lead to
If successful, this study will help doctors understand how BI 1569912 interacts with other drugs, leading to safer dosing recommendations.
What could go wrong
This is a small, early-phase trial in healthy volunteers, not patients. Results may not predict effects in people with illnesses or on other medications.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.